Complement and complement targeting therapies in glomerular diseases

Sofia Andrighetto, Jeremy Leventhal, Gianluigi Zaza, Paolo Cravedi

Research output: Contribution to journalReview articlepeer-review

17 Scopus citations


The complement cascade is part of the innate immune system whose actions protect hosts from pathogens. Recent research shows complement involvement in a wide spectrum of renal disease pathogenesis including antibody-related glomerulopathies and non-antibody-mediated kidney diseases, such as C3 glomerular disease, atypical hemolytic uremic syndrome, and focal segmental glomerulosclerosis. A pivotal role in renal pathogenesis makes targeting complement activation an attractive therapeutic strategy. Over the last decade, a growing number of anti-complement agents have been developed; some are approved for clinical use and many others are in the pipeline. Herein, we review the pathways of complement activation and regulation, illustrate its role instigating or amplifying glomerular injury, and discuss the most promising novel complement-targeting therapies.

Original languageEnglish
Article number6336
JournalInternational Journal of Molecular Sciences
Issue number24
StatePublished - 2 Dec 2019


  • Alternative complement pathway
  • C3 glomerulopathy
  • Complement
  • Complement-targeting therapies
  • Focal segmental glomerulosclerosis
  • Hemolytic uremic syndrome


Dive into the research topics of 'Complement and complement targeting therapies in glomerular diseases'. Together they form a unique fingerprint.

Cite this